DS
NUVB icon

DRW Securities’s Nuvation Bio NUVB Stock Holding History

DRW Securities’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-84,246
Closed -$164K – 1528
2025
Q2 		$164K Buy
+84,246
New +$175K ﹤0.01% 985

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

DRW Securities's NUVB Position: Q3 2025 in Review

DRW Securities sold out of Nuvation Bio (NUVB) in Q3 2025, closing a stake of 84,246 shares — an estimated $164K sold.

DRW Securities first reported a position in NUVB in Q2 2025 and held it in 1 quarter. The position peaked at $164K in Q2 2025. 203 funds tracked by Wall St. Rank hold NUVB as of Q3 2025.

  • DRW Securities reported no remaining Nuvation Bio position as of Q3 2025 after selling out during the quarter.
  • DRW Securities sold 84,246 Nuvation Bio shares in Q3 2025, an estimated $164K.
  • DRW Securities first reported a position in Nuvation Bio in Q2 2025 and held it in 1 quarter.
  • DRW Securities's Nuvation Bio position peaked at $164K in Q2 2025.
  • 203 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2025.

Based on DRW Securities's 13F filing for Q3 2025, filed 14 Nov 2025.